louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02383836: Influence of Position on Detection of Patent Foramen Ovale by Simultaneous Transesophageal Echo and Transcranial Doppler
Official title: Influence of Position on Detection of Patent Foramen Ovale by Simultaneous Transesophageal Echo and Transcranial Doppler
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patent Foramen Ovale
Keywords: Patent Foramen Ovale
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2015-03-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients referred for a TEE with bubble injection to rule out a cardiac source of brain emboli following an acute neurological embolic event.

Brief summary: Patients will have simultaneous Transesophageal Echo (TEE) and Transcranial Doppler (TCD) performed and a comparison of timing, sensitivity and intensity of intravenously injected bubbles will be determined.


Eligibility criteria: Inclusion Criteria:

* Patients needing a TEE evaluation to rule out a cardiac source of brain emboli

Exclusion Criteria:

* Patients unable to comply with protocol requirements
* Patients unable or unwilling to sign informed consent

Primary outcomes:
measure: Bubble Detection
timeFrame: 3 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT05251636: Adjunct Episcleral Brachytherapy for PCV
Official title: A Double-Masked, Multi-center, Active Controlled Safety and Efficacy Study of Adjunct Episcleral Brachytherapy for Polypoid Choroidal Vasculopathy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Age-Related Macular Degeneration
Polypoid Choroidal Vasculopathy
Lead sponsor: Salutaris Medical Devices, Inc.
Sponsor class: INDUSTRY
First posted: 2022-02-23
Enrollment: 159
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate response to anti-VEGF monotherapy.


Eligibility criteria: Inclusion Criteria:

* Active PCV due to nAMD
* Incomplete response to anti-VEGF
* Received at least 3 consecutive and sequential anti-VEGF injections (no missed treatments)
* Ability to undergo ESB intervention

Exclusion Criteria:

* Sub-retinal fibrosis
* Type I or Type II diabetes mellitus
* Previous therapeutic radiation to the head or neck that may have resulted in radiation dose to the retina
* Study eye with BCVA of worse than 20 ETDRS letters (20/400 Snellen)
* Fellow eye with worse BCVA than the study eye or other vision-threatening disease not eligible for treatment
* Receiving anti-VEGF therapy for any reason other than AMD

Primary outcomes:
measure: Best Corrected Visual Acuity (BCVA)
timeFrame: 12 months
Secondary outcomes:
measure: Best Corrected Visual Acuity (BCVA)
timeFrame: 24 months
measure: Central Retinal Thickness
timeFrame: 12 and 24 months
measure: Lesion size
timeFrame: 12 and 24 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06343636: A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease
Official title: A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer&#39;s Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Alzheimer Disease
Lead sponsor: Vigil Neuroscience, Inc.
Sponsor class: INDUSTRY
First posted: 2024-04-02
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927.


Eligibility criteria: Inclusion Criteria:

* The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation
* The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent

Exclusion Criteria:

* The participant has any concurrent disease or condition that, in the opinion of the principal investigator, would make the participant unsuitable for participation in the clinical study

Primary outcomes:
measure: Adverse Events
timeFrame: 28 days post last dose
Secondary outcomes:
Other outcomes:
Locations:
city: Maitland
country: United States
facility: K2 Medical Research
state: Florida
city: Miami
country: United States
facility: Clinical Pharmacology of Miami
state: Florida
city: Melbourne
country: Australia
facility: Nucleus Network
Study officials:
References:
Clinical trial NCT01944436: A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
Official title: Lewy Body Spectrum Disorders: Investigating Neuropsychiatric Benefit and Adverse Effects in Response to Cholinesterase Inhibitors Using Genetics and Brain SPECT
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lewy Body Disease
Keywords: Pharmacogenomics
Dementia with Lewy bodies
Adverse events
Polymorphisms
Acetylcholinesterase
Parkinson's Disease Dementia
Cognitive enhancers
Clinical efficacy
Cytochrome P450
Butyrylcholinesterase
Lead sponsor: Sunnybrook Health Sciences Centre
Sponsor class: OTHER
First posted: 2013-09-17
Enrollment: 57
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Ontario, Canada.

Brief summary: Lewy body spectrum disorders are a common group of neurodegenerative diseases that cause memory loss, behavioural and motor disabilities that impair quality of life. Cognitive enhancers help people afflicted with these conditions. However, some people do not benefit from this treatment, while others experience serious side effects. Side effects and poor response lead to hospitalization and early institutionalization. Pharmacogenomics, the study of how DNA variation can influence drug effects, will be combined with functional changes in brain imaging in response to cognitive enhancers in patients with Lewy body disease. The goal is to develop a predictive test that can be administered in the clinic to aid physicians' choice of initial medication. This can reduce health care costs and improve treatment to Canadians suffering from these devastating disorders.


Eligibility criteria: Inclusion Criteria:

* Inclusion criteria for patients with a Lewy body spectrum disorder includes: age \> 50 years; and mild-moderate dementia (Mini-Mental State Exam \[MMSE\] \> 9); contact on at least four of seven days/week with a responsible caregiver; Hoehn \& Yahr stage ≤ 4.

Exclusion Criteria:

* age \< 50; Severe dementia (MMSE \< 9); contact \< 4 days a week with a responsible caregiver; Hoehn \& Yahr stage \> 4.

Primary outcomes:
measure: Change from baseline in perfusion brain SPECT at 6 months
timeFrame: 0 and 6 months
measure: Change from baseline in neuropsychological assessment scores at 6 months
timeFrame: 0 and 6 months
Secondary outcomes:
measure: Volumetric Brain MRI
timeFrame: Baseline
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Sunnybrook Health Sciences Centre
state: Ontario
Study officials:
References:
Clinical trial NCT06451536: Ga-68 FAPI PET Before Immunotherapy
Official title: Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Mesotheliomas Pleural
Lead sponsor: Ankara University
Sponsor class: OTHER
Collaborators: name: Liv Hospital Ankara
name: Social Sciences University of Ankara
name: Ankara Yildirim Beyazıt University
First posted: 2024-06-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: prediction of immunotherapy response with Ga-68 FAPI PET
Primary purpose: DIAGNOSTIC

Brief summary: It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.

Detailed description: Patients diagnosed with pleural mesothelioma and planned for immunotherapy will be included in the study. Patients will undergo Ga68 FAPI PET/CT imaging within 10 days before the start of immunotherapy treatment, and SUVmax, SUVmean, metabolic tumor volume and total Ga68 FAPI uptake parameters will be obtained from the tumors. Following this, the routine treatment and follow-up of the patients will be carried out by their clinicians. It will be evaluated whether there is a correlation between treatment response and initial Ga-68 FAPI PET findings.

Eligibility criteria: Inclusion Criteria:

* Having a histopathologically confirmed diagnosis of
* Pleural Mesolthelioma
* Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
* Patients who gave informed consent form to participate in the study

Exclusion Criteria:

* ECOG\>2
* Patients who did not provide informed consent form to participate in the study

Primary outcomes:
measure: Prediction of immune therapy response with Ga-68 FAPI PET
timeFrame: 6. month after initiation of therapy
measure: Prediction of immune therapy response with Ga-68 FAPI PET
timeFrame: 6. month after initiation of therapy
measure: Prediction of immune therapy response with Ga-68 FAPI PET
timeFrame: 6. month after initiation of therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara University School of Medicine
Study officials:
References:
Clinical trial NCT05330936: Comparison of Cyanocobalamin in Avocado Oil Cream With Steroid Combination Ointment
Official title: Comparison of Cyanocobalamin in Avocado Oil Cream With Steroid Combination Ointment in the Treatment of Chronic Plaque Psoriasi-A Randomized Clinical Trial in Tertiary Care Hospital
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Plaque Psoriasis
Lead sponsor: Pak Emirates Military Hospital
Sponsor class: OTHER
First posted: 2022-04-15
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized clinical trial
Primary purpose: TREATMENT

Brief summary: A randomized clinical trial with two groups. Group A Group B Group A is being treated with conventional Steroid combination ointment for the treatment of chronic Plaque Psoriasis.

Group B is being treated with Cyanocobalamin in Avocado Oil cream for the treatment of chronic Plaque Psoriasis.

Each group having 45 patients.

Detailed description: Outcome is being measured by PASI Score calculation with monthly follow up.

Eligibility criteria: Inclusion Criteria:

* Age bracket (18-60 years)
* Non psoriatic Arthritis
* No oral Retinoids

Exclusion Criteria:

* pregnancy
* Malignancy
* Body surface area involving \>50%

Primary outcomes:
measure: Efficacy and tolerability of steroids as compared to Avacado Oil Cream
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: PakEmiratesMH
state: Punjab
Study officials:
affiliation: Pak Emirates Military Hospital
name: Qamar ud din Khan, MBBS,FCPS
role: STUDY_DIRECTOR
References:
Clinical trial NCT01597336: Treatment of Abdominal Abscesses With or Without Fibrinolysis
Official title: Treatment of Abdominal Abscesses With or Without Fibrinolysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Abscess
Tissue Plasminogen Activator
Keywords: abscess
tPA
Lead sponsor: Children's Mercy Hospital Kansas City
Sponsor class: OTHER
First posted: 2012-05-14
Enrollment: 92
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate the utility of fibrinolysis when draining an abdominal abscess as defined by length of stay after drainage.

Detailed description: The hypothesis is that fibrinolysis of a abscess will shorten hospital stay compared to drainage alone.

Eligibility criteria: Inclusion Criteria:

* Patients under age 18 found to have an abscess in their abdomen related to perforated appendicitis that requires a drain either prior to or after appendectomy.

Exclusion Criteria:

* Patients with known immune deficiency per medical record review
* Patients with another condition affecting surgical decision making or recovery
* Patients with drain unable to be placed

Primary outcomes:
measure: Length of hospital stay
timeFrame: 1-2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Children's Mercy Hospital
state: Missouri
Study officials:
affiliation: Children's Mercy Hospital and Clinics
name: Shawn D St. Peter, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00773136: Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
Official title: Effect of Bimatoprost (Lumigan) in Gel Suspension Applied to the Eyelashes on Eyelash Growth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertrichosis
Keywords: Bimatoprost
Eyelash lengthening
Prostaglandin Analogs
Cosmetics
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2008-10-16
Enrollment: 21
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Objective: To determine if Lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened and those who met inclusion criteria were enrolled. Each participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with GonakTM gel and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the eyelashes every evening on the designated eye for 6 weeks. Lash length was measured with a caliper at enrollment, at weekly intervals during the study and at 1 and 3 months after study completion. Visual acuity, ocular symptoms, intraocular pressure and photographs were documented at these same intervals. Results: The average eyelash growth in the Lumigan group was 2.01mm (vs. control average of 1.13mm) which was a statistically significant difference (p=0.009). The average intraocular pressure decreased equally in both groups (2.14 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Discussion: Our data showed an increase in eyelash length with use of Lumigan in gel suspension, suggesting that it may have eyelash lengthening properties.

Detailed description: Study completed

Eligibility criteria: Inclusion Criteria:

* Age greater than 20 and less than 90 and patients who have previously used and are comfortable with applying mascara.

Exclusion Criteria:

* History of glaucoma, uveitis, pregnancy, allergic reaction to prostaglandins or the gel suspension, alopecia, and previous usage of other eyelash growth enhancement.

Primary outcomes:
measure: Efficacy of Bimatoprost in Lengthening of Eyelashes
timeFrame: 4.5 months (6 weeks of drug application and 3 months after discontinuing)
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami, Bascom Palmer Eye Institute
state: Florida
Study officials:
affiliation: University of Miami
name: Wendy W Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06253936: Prevalence of Anatomical Variants of Dural Sinuses by Magnetic Resonance Venography Evaluation in Sohag
Official title: Prevalence of Anatomical Variants of Dural Sinuses by Magnetic Resonance Venography Evaluation in Sohag
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Anatomical Variants of Dural Sinuses by Magnetic Resonance Venography
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-02-12
Enrollment: 169
Sex: ALL
Minimum age (years): 7
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Sohag by nationality and residence, male or female by sex, having normal cerebral MRV reported and consented to participate in the research work will be included in this research.

Brief summary: MR cerebral venography (MRV) is an MRI examination of the head with either contrast-enhanced or non-contrast sequences to assess patency of the dural venous sinuses and cerebral veins.


Eligibility criteria: Inclusion Criteria:

* Sohag by nationality and residence, male or female by sex, having normal cerebral MRV reported and consented to participate in the research work will be included in this research.

Exclusion Criteria:

* Having the diagnosis of cerebral venous sinus thrombosis, and previous head injury are the exclusion criteria of this research, also patients with absolute or relative contraindications for imaging including; claustrophobia, metallic implants, pacemaker and prosthetic heart valves for MRI.

Primary outcomes:
measure: Number of anatomical variants of dural sinuses by Magnetic Resonance Venography evaluation in Sohag
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university hospital
Study officials:
References:
Clinical trial NCT01675336: Genetics of Periodontal Diseases in Chinese (Taiwan)
Official title: The Association Between Interleukin-1 Gene Variations and Adult Chronic Periodontal Disease in Chinese (Taiwan))
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Periodontal Disease
Lead sponsor: Kaohsiung Medical University
Sponsor class: OTHER
Collaborators: name: Interleukin Genetics, Inc.
First posted: 2012-08-29
Enrollment: 400
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All study subjects will be selected from a pre-existing patient database in Taiwan. All chronic periodontitis cases and controls will be subjects who were at least 35 years old at time of enrollment.

Classification of chronic periodontitis will be based on the extent of periodontal tissue destruction with consideration of tooth loss.

Brief summary: A retrospective case control study to validate the association between Interleukin-1 gene variations and adult chronic periodontal disease in Chinese (Taiwan).


Eligibility criteria: Inclusion Criteria:

* To be included in this study, an individual needs to be Han Chinese of 35 years of age or older at time of enrollment.

Exclusion Criteria:

* Subjects who, at time of enrollment, were pregnant or breastfeeding, or needed antibiotic prophylaxis before periodontal treatment will be excluded from this study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: employee
name: Ya-Ping Ho, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05353036: Survey to Identify Substance Use in Teenagers and Adolescents
Official title: Expanded Preoperative Survey During Perioperative Care to Identify Substance Use in Teenagers and Adolescents
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2022-04-29
Enrollment: 250
Sex: ALL
Minimum age (years): 12
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adolescents undergoing procedure requiring anesthesia at Nationwide Children's Hospital.

Brief summary: This is a prospective survey study of patients 12-21 years undergoing anesthetic care. The primary objective is to determine the incidence of illicit substance use and abuse prior to anesthetic care. The secondary objective is to determine the illicit substances used and their frequency in patients presenting for anesthetic care.

Detailed description: The participants will be asked to complete a survey in REDCap using an iPad during the visit. The study will record any positive answers from the drug and tobacco use questions routinely asked of the parents during the on-line pre-admission testing process. These include yes/no answers regarding drug, alcohol, and tobacco use.

The information collected will include only demographic data including age, weight, gender, ethnicity/race, and zip code. Survey data will be coded and will not include patient information. Completion of the survey will take approximately 15-20 minutes.

Eligibility criteria: Inclusion Criteria:

* Patients 12-21 years of age
* Presenting for surgery or procedure requiring anesthesia

Exclusion Criteria:

* Patients who are not able to complete the computerized survey due to physical or intellectual impairment
* Patients who are non-English speaking

Primary outcomes:
measure: Number of Participants With Adolescent and Parent Reported Alcohol, Drug, Vaping and Tobacco Usage
timeFrame: Baseline
measure: Alcohol Use
timeFrame: Baseline
measure: Marijuana Use
timeFrame: Baseline
measure: Vape Pen Use
timeFrame: Baseline
measure: Tobacco Use
timeFrame: Baseline
measure: Prescription Opioid Use for Acute Pain
timeFrame: Baseline
Secondary outcomes:
measure: Most Recent Alcohol Use
timeFrame: Baseline
measure: Age First Drank Alcohol
timeFrame: Baseline
measure: Most Recent Marijuana Use
timeFrame: Baseline
measure: Age First Used Marijuana
timeFrame: Baseline
measure: Most Recent Vape Pen Use
timeFrame: Baseline
measure: Age First Started Vaping
timeFrame: Baseline
measure: Most Recent Tobacco Use
timeFrame: Baseline
measure: Age First Used Tobacco
timeFrame: Baseline
measure: Most Recent Prescribed Opioid Use
timeFrame: Baseline
measure: Prescribed Opioid Use for Anything Other Than Pain
timeFrame: Baseline
measure: Prescribed Opioid Use Leading to Abuse
timeFrame: Baseline
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References: